Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
HRH3 11255 MIRTAZAPINE CHEMBL654 antagonist DrugBank 15771415, 10762339, 3419539, 20945968
HRH3 11255 BETAHISTINE CHEMBL24441 antagonist TdgClinicalTrial, DrugBank 18447604, 20530654, 11700150
HRH3 11255 CIPRALISANT MALEATE CHEMBL2106003 agonist ChemblInteractions
HRH3 11255 PF-03654764 CHEMBL2206292 antagonist ChemblInteractions
HRH3 11255 CHEMBL1767164 CHEMBL1767164 TdgClinicalTrial
HRH3 11255 GSK239512 CHEMBL3092650 antagonist ChemblInteractions
HRH3 11255 HISTAMINE CHEMBL90 agonist DrugBank 16599255, 17575572, 17652997, 16715497
HRH3 11255 GSK189254 CHEMBL517140 antagonist ChemblInteractions
HRH3 11255 BAVISANT CHEMBL2103862 antagonist ChemblInteractions
HRH3 11255 JNJ-17216498 CHEMBL3545030 antagonist ChemblInteractions
HRH3 11255 IRDABISANT CHEMBL1829335 antagonist ChemblInteractions
HRH3 11255 PF-03654746 CHEMBL2151197 antagonist ChemblInteractions
HRH3 11255 MK-0249 CHEMBL476323 inverse agonist ChemblInteractions
HRH3 11255 ABT-288 CHEMBL3545029 antagonist ChemblInteractions
HRH3 11255 TIPROLISANT CHEMBL462605 inverse agonist ChemblInteractions

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
HRH3 rs3787429 T risperidone efficacy no Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C. 28696411 1450928241
HRH3 rs3787429 TT risperidone efficacy yes Response was measured by reduction in Brief Psychiatric Rating Scale (BPRS) scores after 4 and 8 weeks of treatment. The statistical analysis comparing genotypes with score reductions was completed using ANOVA, so the p-value quoted is for association between all three genotypes and score reduction. It is therefore unclear which set of two genotypes have significantly different score reductions. The difference in reduction between genotypes was not significantly different after 8 weeks of treatment. Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT. 21652606 981501287
HRH3 rs3787430 TT risperidone efficacy yes Response was measured by reduction in Brief Psychiatric Rating Scale (BPRS) scores after 4 and 8 weeks of treatment. The statistical analysis comparing genotypes with score reductions was completed using ANOVA, so the p-value quoted is for association between all three genotypes and score reduction. It is therefore unclear which set of two genotypes have significantly different score reductions. Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT. 21652606 981501278